Brought to you by:
New meta-analysis finds ‘no observed difference’ in mortality between paclitaxel and uncoated device use in CLTI patients
February 2020 brings another paclitaxel device meta-analysis of randomized controlled trials in chronic limb-threatening ischemia (CLTI) patients. Krystal Dinh, BMed, of Westmead Hospital, Sydney, Australia, et al report online ahead of print that the risk of all-cause mortality after treatment with…
Global vascular guidelines for CLTI are gaining traction but work remains to raise awareness and delivery of care
The application of new global vascular guidelines for chronic limb-threatening ischemia (CLTI) provides an opportune and worthwhile window to revisit the concept of critical limb ischemia (CLI) along with its implications as a worldwide healthcare issue. Peripheral arterial disease (PAD)…